Vidofludimus | B1633

Vidofludimus is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.

Vidofludimus is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.

B1633 | Vidofludimus DataSheet

Alternate Name/Synonyms: Vidofludimus; 4SC-101; 4SC 101; 4SC101; SC12267; SC 12267, SC-12267; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid

Appearance: Solid

Formulation: N/A

CAS Number: 717824-30-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₀H₁₈FNO₄

Molecular Weight: 355.36

Cell-Permeable?: Yes

Purity: >98%

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A novel immunosuppressive drug

MDL Number: MFCD18633262

PubChem CID: 9820008

SMILES: COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F

InChi: 1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)

InChi Key: XPRDUGXOWVXZLL-UHFFFAOYSA-N